Psoriasis | Emerging Therapies | Tremfya Launch Tracking Wave 2 (US)

Publish date: March 2018

Login to access report

In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as IL-12/23 inhibitor Stelara (Janssen), have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents—Celgene’s Otezla (2014), Novartis’s Cosentyx (2015), Eli Lilly’s Taltz (2016), Valeant’s Siliq (2017), Janssen’s Tremfya (2017), and Sun Pharma’s Ilumya (2018)—is anticipated to substantially alter the market landscape. The Psoriasis Emerging Therapies series includes three waves that will track the awareness, trial, and use of Tremfya after its launch in July 2017 for the treatment of psoriasis. In addition, the series will examine physicians’ anticipation of future trends in psoriasis treatment, particularly Tremfya’s uptake, and assess Janssen’s promotional efforts.

Questions Answered:

  • What is the awareness of, familiarity with, and perceptions related to Tremfya among U.S. dermatologists?
  • According to prescribers, to which patients are they prescribing Tremfya, why are they prescribing Tremfya, and how satisfied are they with Tremfya ?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Tremfya tracking compared to other recent product launches in the autoimmune market?

Product Description:

Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and use of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Table of contents

  • Tremfya Launch Tracking Wave 2 (US)
    • Key Findings
    • Benchmarking Tremfya's Launch Success vs. Other Launched Drugs
      • Benchmarking Tremfya's Launch Success vs. Other Launched Drugs
    • Prescriber and Nonprescriber Profiles
      • Differences Between Tremfya Prescribers and Nonprescribers
    • Tremfya Awareness and Perceptions
      • Unaided and Aided Awareness of Tremfya
      • Familiarity with Tremfya
      • Sources of Familiarity with Tremfya
      • Initial Reaction to and Interest in Tremfya
      • Impressions of Tremfya
      • Prescriber and Nonprescriber Profiles
    • Tremfya Trial and Use
      • Willingness to Prescribe Tremfya
      • Number of Patients Currently Receiving Tremfya
      • Reasons for Not Yet Prescribing Tremfya
      • Anticipated Tremfya Use
      • Tremfya Performance on Key Attributes
    • Effectiveness of Face-to-Face Detailing for Tremfya
      • Tremfya Sales Representative Frequency and Reach
      • Satisfaction with Tremfya Sales Representative
      • Tremfya Message Recall
    • Methodology
      • Primary Market Research Methodology
      • Physician Demographics
    • Appendix
      • Additional Primary Market Research

Author(s): Mohit Nasa, MBA

Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis. He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.